Altasciences Expands Bioanalytical Labs in North America

Editor’s Take: Global pharmaceutical companies continue to pour hundreds of billions of dollars into U.S. manufacturing, R&D and supply chain infrastructure to localize production and bolster domestic capacity.

Altasciences is expanding its North American bioanalytical laboratory footprint with a 4,000-square-foot addition to the company’s laboratory in Greater Montréal and a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania.

The lab in Canada is expected to be fully operational by the end of Q3 2026, while construction on the Pennsylvania site will proceed in phases, with Phase 1 scheduled for completion in Q1 2027.

These investments significantly increase Altasciences’ ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience.

Supporting Demand for Sophisticated Bioanalytical Support

Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studies and higher sample volumes while incorporating “state-of-the-art” instrumentation and advanced laboratory automation for pharmacokinetic and pharmacodynamic assay method development, validation, and sample analysis across the clinical phases of drug development.

“Our clients are bringing increasingly complex molecules into development, and that is driving unprecedented demand for sophisticated bioanalytical support,” said Lynne Le Sauteur, Vice President, Laboratory Sciences, Altasciences. “We’re investing ahead of that demand by expanding capacity where sponsors need it most and deploying state-of-the-art instrumentation and automation that enhances speed without compromising quality.”

The expansion project strengthens Altasciences’ broader North American bioanalytical network, which includes established laboratories in Greater Montréal (Quebec), Seattle (Washington), and Columbia (Missouri). Together, these locations provide sponsors with bioanalytical expertise and capacity across the drug development continuum.

Meanwhile, network-wide harmonization enables sponsors to leverage capacity across locations, transition work seamlessly between laboratories, and maintain complete confidence in the integrity and consistency of their bioanalytical data.

“This investment is about far more than expanding laboratory space,” said Robert Sabelli, Co-Chief Operating Officer, Altasciences. “We’re building one of the industry’s most integrated and scalable bioanalytical networks. As clinical programs become larger, more complex, and increasingly global, sponsors need a partner that can rapidly scale capacity while delivering consistent scientific excellence across every location. That’s exactly what we’re delivering.”